Bioponic Phytoceuticals CEO Issues Letter to Shareholders

MAUI, Hawaii, Nov. 29 /PRNewswire-FirstCall/ -- Bioponic Phytoceuticals, Inc. (Pink Sheets: BPYT) ("Bioponic"), an innovative provider of natural products and patented technology serving the Complementary Alternative Medicine (CAM) and nutraceutical markets, issued today a letter to shareholders from CEO and Chairman Steven M. Schorr to discuss the Company's material developments during 2007.

Dear Shareholders:

I have great enthusiasm about Bioponic's achievements to-date, and the outlook for the natural products and phytochemical production industry as a whole. Pharmaceuticals derived from plants account for over 0 Billion in sales in the U.S. alone, and demand for plant-derived medicinals is on the rise worldwide. By 2010, global sales of nutritional preparations and natural medicine will top nearly 00 Billion. Bioponic has over 94 proprietary products in commercial production through our unique Bioresonant Phytotherapeutic(TM) formulas and our proprietary Airponic Growth System that enables the in-house production of the highest quality health and wellness products.

I believe the following achievements during 2007 are leading up to an extraordinary year of growth for the Company and its shareholders in 2008:

-- This month, we launched Curemisinin(TM), an all-natural artemisinin-based treatment for malaria. Alternative anti-malaria medicines are in dire need in places like Africa, where every 30 seconds a child dies of the disease. According to the World Health Organization (WHO), "The inappropriate use of anti-malarial drugs in the past century contributed to widespread resistance in the malaria parasite to drugs such as chloroquine, leading to rising rates of sickness and death. Over the past decade, a new group of antimalarials-- known as artemisinin-based combination therapies -- has brought new hope in the fight against malaria." (http://www.who.int/features/factfiles/malaria/en/index.html) -- Representatives from the American Friends of Guinea began distributing Curemisinin to clinics in Conakry, the capital city of Guinea, Africa. These human clinical trials will record the efficacy of Curemisinin, an important step toward partnering with WHO and other organizations that can aide Bioponic in bringing Curemisinin into countries where it is needed most. -- Our flagship product Flight Spray(R) is on the heels of a mass-market launch into national retail outlets, including major health food chains, top-name pharmacies and drug stores, beginning in the first quarter of 2008. -- Our Master Broker for the Western U.S., Active Sales and Marketing of Southern California, will expand our retail channels for six of our core product lines to 1,000 or more of the nation's top health food stores in the Western region. We anticipate this agreement can add .5 Million in sales to Bioponic in 2008. -- This month also marked the launch of our first product suite geared specifically for newborns and infants called Gentle Mother(TM). Gentle Mother, a suite of five products that treat common ailments of babies, is available for purchase online and will be rolled out to 1,000 or more national retail chains beginning in 2008. -- Entered into a 00,000 exclusive production and sales agreement with Malie, Inc. of Kauai, Hawaii to manufacture Malie's new Facial Tonic product line using Bioponic's proprietary ingredients and formulations. -- Received an initial order from Singapore-based Muji Global Sourcing Pte. Ltd. ("Muji"), who will be selling several Bioponic product lines throughout its established territories in Asia. -- Developed Curecumin(TM), a Bioresonant Phytotherapeutic(TM) formula designed to treat Alzheimer's Disease and the five leading forms of cancer (breast, colon, lung, prostate and skin cancers) -- Continue to develop our portfolio of intellectual properties with the acquisition of trademarks for our branded products and patent pending status for our Bioresonant Phytotherapeutic technology.

From our local Hawaiian facility, we are capable of processing 50 Million worth of wholesale products. With new global distribution channels and the introduction of cutting-edge products such as Curemisinin, our scalable production capacity will enable us to meet current demand, fill orders and pursue OEM/private label agreements with companies like Malie Inc. who are utilizing our formulation and manufacturing expertise to bring their natural cosmetic products to market.

I encourage you to learn more about our unique technologies, product lines and active ingredients by visiting our website and online store at http://www.bioponic.com/. I hope you'll find this additional information useful in understanding Bioponic and the immense potential it represents for you as a shareholder. As always, I thank you for your time, interest and continued support in Bioponic.

In good health, Steven Schorr Chairman and Chief Executive Officer About Bioponic Phytoceuticals

Bioponic Phytoceuticals is engaged in the development, production and distribution of Bioresonant Phytotherapeutic(TM) products. The Company has developed several branded product lines, including the nasal spray: Flight Spray(R) (http://www.flightspray.com/); Curecumin(TM) (a treatment for Alzheimer's Disease); O-Spray(TM) (scented nasal sprays); Throat Note(TM) (formulated for professional speakers and singers, great for everyone!) and the effective natural skincare product Hawaiian Healing Mist(TM). Bioponic is focused on the production of natural products that are used to promote health and well being.

All statements other than statements of historical fact included in this press release are "forward-looking statements" within the meaning of federal securities laws. Such forward-looking statements are subject to a number of risks and uncertainties, some of which are beyond the Company's control.

CONTACT: Steven M. Schorr, CEO, Bioponic Phytoceuticals, 1-808-876-1711, info@bioponic.com or Geoffrey Eiten, Investor Relations, OTC Financial Network, 781-444-6100x613, geiten@otcfn.com, http://www.otcfn.com/bpyt.

Bioponic Phytoceuticals, Inc.

CONTACT: Steven M. Schorr, CEO of Bioponic Phytoceuticals, Inc.,
1-808-876-1711; or investors, Geoffrey Eiten of OTC Financial Network,
1-781-444-6100, ext. 613, geiten@otcfn.com, for Bioponic Phytoceuticals,
Inc.

Web site: http://www.bioponic.com/
http://www.who.int/features/factfiles/malaria/en/index.html
http://www.flightspray.com/